ANL 33.80 Increased By ▲ 1.05 (3.21%)
ASC 15.13 Increased By ▲ 0.75 (5.22%)
ASL 25.50 No Change ▼ 0.00 (0%)
AVN 95.50 Decreased By ▼ -0.20 (-0.21%)
BOP 9.17 Increased By ▲ 0.02 (0.22%)
BYCO 10.23 Increased By ▲ 0.25 (2.51%)
DGKC 137.50 Increased By ▲ 2.20 (1.63%)
EPCL 51.62 Increased By ▲ 0.37 (0.72%)
FCCL 25.00 Increased By ▲ 0.31 (1.26%)
FFBL 25.45 Increased By ▲ 0.95 (3.88%)
FFL 15.70 Increased By ▲ 0.28 (1.82%)
HASCOL 10.90 Increased By ▲ 0.18 (1.68%)
HUBC 86.75 Increased By ▲ 0.01 (0.01%)
HUMNL 7.10 No Change ▼ 0.00 (0%)
JSCL 27.04 Increased By ▲ 0.45 (1.69%)
KAPCO 40.00 Increased By ▲ 0.80 (2.04%)
KEL 4.15 Increased By ▲ 0.04 (0.97%)
LOTCHEM 14.80 Increased By ▲ 0.08 (0.54%)
MLCF 47.59 Increased By ▲ 0.75 (1.6%)
PAEL 38.30 Increased By ▲ 1.20 (3.23%)
PIBTL 11.91 Increased By ▲ 0.08 (0.68%)
POWER 10.70 Increased By ▲ 0.20 (1.9%)
PPL 90.97 Decreased By ▼ -0.53 (-0.58%)
PRL 27.45 Increased By ▲ 1.63 (6.31%)
PTC 8.81 Decreased By ▼ -0.09 (-1.01%)
SILK 1.40 No Change ▼ 0.00 (0%)
SNGP 43.75 Increased By ▲ 2.68 (6.53%)
TRG 147.70 No Change ▼ 0.00 (0%)
UNITY 31.20 Increased By ▲ 0.72 (2.36%)
WTL 1.52 Decreased By ▼ -0.02 (-1.3%)
BR100 5,016 Increased By ▲ 30.84 (0.62%)
BR30 26,130 Increased By ▲ 297.73 (1.15%)
KSE100 46,158 Increased By ▲ 193.53 (0.42%)
KSE30 19,308 Increased By ▲ 71.8 (0.37%)
Business & Finance

Covid-19 Vaccines to develop into a Multibillion-Dollar market in 2021: Fitch

  • “Coupled with the unparalleled demand, these products will help to develop Covid-19 vaccines into a multibillion-dollar commercial opportunity,” it stated.
07 Jan 2021

As the ongoing Covid-19 pandemic has accelerated rapid changes in healthcare system including the need for a safe and effective vaccine to help countries return to pre-Covid-19 levels of business and social activity.

Fitch Solutions in its latest report titled The Year Ahead: Global Industries Outlook 2021, expects that the coronavirus vaccines providing higher efficacy results would become a major commercial market in the ongoing year.

Throughout November 2020, three vaccine developers, Pfizer/BioNTech, Moderna and AstraZeneca reported positive efficacy results from Phase III clinical trials. In early December 2020, the first Covid-19 vaccine developed by Pfizer and its commercial partner BioNTech, was approved by the UK’s medicine regulator.

Over 2021, Fitch Solutions expect a large number of further approvals, for both Pfizer’s vaccine and others utilising the same or different technologies. “Coupled with the unparalleled demand, these products will help to develop Covid-19 vaccines into a multibillion-dollar commercial opportunity,” it stated.

The report forecasted that the Covid-19 vaccine market to initially develop along the lines of agreements in place between governments and vaccine manufacturers, which stipulate vaccine supply for a pre-agreed price per dose.

“We have recently highlighted the now nearly 100 deals in which price per dose has varied considerably as per the chart above. Given that governments are viewing vaccines as the catalyst for economic recovery, companies with the most effective vaccines will be able to command relatively high prices for Covid-19 vaccine products,” the report said.

It highlighted that some companies have opted for a more conservative approach to pricing to ensure broad access. For the most part though pricing will reflect efficacy, safety, dosing, and transit conditions which will all play a role in demand for a given product.

“Overall, we expect, distribution to continue across three-speeds largely dependent on level of economic development. Over the longer term, prices will taper as more products enter the market,” it said.